Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction.
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction.
复制标题
肠道微生物群为炎症性肠病诊断和英夫利昔单抗反应预测提供跨种族的通用生物标志物
DOI：
10.1128/msystems.00188-17
复制
发表时间：
2018-01
期刊：
影响因子：
6.4
通讯作者：
Chen Y
中科院分区：
文献类型：
--
作者：
Zhou Y;Xu ZZ;He Y;Yang Y;Liu L;Lin Q;Nie Y;Li M;Zhi F;Liu S;Amir A;González A;Tripathi A;Chen M;Wu GD;Knight R;Zhou H;Chen Y
在本报告中，我们展示了人类粪便微生物区系包含有希望的和通用的生物标志物，用于非侵入性评估炎症性肠病的严重性和IFX治疗效果，强调挖掘肠道微生物区系作为对IBD患者进行分层和应用个性化治疗以获得最佳结果的潜在能力。肠道微生物区系失调是炎症性肠病(IBD)发病和持续存在的重要原因。鉴于肠道微生物群因地理和种族不同而不同，目前尚不清楚是否存在用于IBD诊断和预后评估的通用微生物特征，而不考虑人群。在这里，我们描述了一系列中国IBD患者的粪便微生物区系，并将他们与两个西方IBD队列(PRISM和RISK)相结合进行荟萃分析。我们发现，中国人和西方人IBD的肠道微生物变化模式相似。我们基于肠道微生物组的IBD诊断预测模型在队列中是稳健的，在克罗恩病(CD)和溃疡性结肠炎(UC)患者中的预测准确率分别为87.5%和79.1%。放线杆菌和变形杆菌(肠杆菌科)水平的相对增加和非细菌(梭状杆菌)水平的相对下降与IBD的严重程度密切相关(P<；0.05)。此外，与复发者相比，对英夫利昔单抗(IFX[Remicade])有反应的患者肠道微生物区系多样性得到恢复，梭菌相对丰度显著增加。此外，某些微生物，主要是梭状芽孢杆菌，单独预测治疗效果的准确率为86.5%，结合钙保护素水平和克罗恩病活动指数(CDAI)预测治疗效果的准确率为93.8%。综合以上结果，我们得出结论，肠道微生物区系可以为IBD的诊断、疾病活动性评估和英夫利昔单抗治疗反应预测提供一套通用的生物标志物。在本报告中，我们表明人类粪便微生物区系包含有希望的和通用的生物标记物，用于非侵入性评估炎症性肠病的严重性和IFX治疗效果，强调挖掘肠道微生物区系作为对IBD患者进行分层和应用个性化治疗以获得最佳结果的潜在能力。
In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.